<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02231762</url>
  </required_header>
  <id_info>
    <org_study_id>A-94-52030-268</org_study_id>
    <secondary_id>2013‐001697‐17</secondary_id>
    <nct_id>NCT02231762</nct_id>
  </id_info>
  <brief_title>Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET</brief_title>
  <acronym>SONNET</acronym>
  <official_title>Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and tolerability of the combination of
      Lanreotide Autogel 120 mg and Temozolomide in patients with progressive
      gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) graded as G1 or G2 (G1/G2). All
      progressive tumours classified according to Response Evaluation Criteria In Solid Tumours
      (RECIST, 1.1).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate after 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Disease control rate is the total proportion of patients in each category of response i.e. Complete response + partial response + stable disease as measured by the central radiologist using (RECIST, 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate after 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Disease control rate is the total proportion of patients in each category of response i.e. Complete response + partial response + stable disease as measured by the central radiologist using (RECIST, 1.1). [6 months combination treatment followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months wait and see].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression or death</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with normalized and stabilized Chromogranin A (CgA) levels after 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as less than 50% increase of CgA level compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with normalized and stabilized CgA-levels after 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as less than 50% increase of CgA level compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to partial response within 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete response within 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of partial response within 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response within 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change (greater than or equal to 50%) from baseline in CgA reduction at 12 months</measure>
    <time_frame>Baseline, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency of symptomatic episodes of diarrhoea after 6 months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Frequency of the symptomatic episodes assessed by the mean of the last 3 days before the patient visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency of symptomatic episodes of flushing after 6 months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Frequency of the symptomatic episodes assessed by the mean of the last 3 days before the patient visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency of symptomatic episodes of diarrhoea after 12 months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Frequency of the symptomatic episodes assessed by the mean of the last 3 days before the patient visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency of symptomatic episodes of flushing after 12 months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Frequency of the symptomatic episodes assessed by the mean of the last 3 days before the patient visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Quality of Life (QoL)</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>QoL assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) and Quality of Life Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Gastroenteropancreatic Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Lanreotide Autogel 120mg &amp; Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.
Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide Autogel 120 mg</intervention_name>
    <description>Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).</description>
    <arm_group_label>Lanreotide Autogel 120mg &amp; Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide (TMZ)</intervention_name>
    <description>Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.</description>
    <arm_group_label>Lanreotide Autogel 120mg &amp; Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent prior to any study related procedures

          -  Inoperable, Gastro-Entero-Pancreatic-Neuroendocrine Tumour G1 or G2 (Proliferation
             Index, Ki67-Index: 0 to ≤20%) confirmed by pathological/histological assessment

          -  Progressive disease within 12 months before inclusion (RECIST 1.1: increase of &gt;20%
             tumour load; by Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)

          -  Measurable disease according to RECIST 1.1.

          -  Metastatic disease confirmed by CT/MRI.

          -  Functioning or non-functioning NET (G1, G2).

          -  Positive Octreo-Scan (≥ Grade 2 Krenning scale) or positive DOTA
             (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-TATE (Tyr3-Thre8-Octreotide
             or DOTA-Tyr3-octreotate)/TOC (Tyr3-octreotide) -PET (Positron-Emission-Tomography) -CT
             within 12 months prior to screening

        Exclusion Criteria:

          -  Has the diagnosis of Insulinoma

          -  Has a diagnosis of a multiple endocrine neoplasia (MEN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Hoffmanns, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vienna General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENDOC Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncological Center Leer</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2014</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

